- Clinical Trials
The focus of research at the University of Adelaide’s Discipline of Psychiatry is regeneration of the capacity of human mind and brain. This approach is supported by 3 main pillars of research: Psychiatric Neuroscience, Clinical Psychiatry and Translational Psychiatry.
The Queen Elizabeth, Lyell McEwin and Royal Adelaide Hospital divisions of the University of Adelaide’s Discipline of Psychiatry have developed an integrated research program, led by Head of Discipline Professor Bernhard Baune.
Research projects at the BHI are coordinated by clinical academic Dr Scott Clark and include:
- Clinical Psychiatry: these projects provide high quality clinically relevant assessments and conduct longitudinal clinical studies in patients with severe mental illness
- Translational Psychiatry: these projects integrate basic science to provide improved diagnostics and develop novel treatments for Psychiatric Disorders.
We are always looking for exceptional students who have an interest in clinical and translational psychiatry to join our research team for honours or PhD projects.
Potential PhD or Honours students are welcome to contact Dr Scott Clark to find out more about any of the projects.
Student Alumni (since 2018)
|Kaitit Tan||Honours, First Class, The University of Adelaide||2018||EEG and TMS/EEG biomarkers of cognition, symptoms and function in major depression||Clark SR, Goldsworthy M|
|Diana Bol||Honours, First Class, The University of Adelaide||2018||EEG and TMS/EEG biomarkers of cognition, symptoms and function in bipolar disorder||Clark SR, Schubert KO, Goldsworthy M|
This study investigates the effects of depression and anxiety on a person’s mental status and capacity by analysing psychological, and functional genetic differences in a healthy cohort and those suffering from mood and anxiety disorders.
In current clinical practice it is impossible to predict individual course of psychotic illness or treatment response. This longitudinal study assesses patients at different stages of psychotic illness to develop accurate biomarkers of risk profile, transition between disease stages and potential for functional recovery.
This study investigates the impact of Aripiprazole depot for treatment of schizophrenia and schizoaffective disorder. The study is funded by Lunbeck, with the main aim of identifying predictors of treatment outcome. The study involves an assessment of psychopathology, cognitive and general function along with blood sampling and a brief physical examination.
Interested participants should contact the research team.
Ph: +61 8 8313 7676
This study uses data linkage of existing information in public clinical services to provide a detailed understanding of treatment processes and outcomes in those with chronic psychosis treated with oral clozapine in comparison to long acting injectable (depot) antipsychotics.
Anti-inflammatory treatment of inflammation associated depression (PREDDICT)
This study investigates the efficacy of the novel antidepressant Vortioxetine for Major Depressive Disorder (MDD). In addition, this study also evaluates whether the adjunction of an anti-inflammatory medication improves the efficacy of the antidepressant medication in reducing depressive symptoms in patients with MDD. The rational is that anti-inflammatory add-on therapy has previously demonstrated beneficial effects in the treatment of MDD.
This study includes people aged between 18 – 70 years of age suffering from depression. Interested participants should contact the research team, and read this Participant Information Sheet.
Ph: +61 8 8313 7676
The Cognitive and Emotional Recovery Training Program for Depression (CERT-D)
This study evaluates the clinical efficacy of a novel psychological treatment approach for Major Depressive Disorder (MDD). The rationale is that targeted treatment in the domains of cognition, emotion processing, and social cognition will result in improved psychosocial functioning (e.g., social relationships, organisation, productivity) and overall mental health.
This study includes people 18-75 years of age with current Depression. Interested participants should contact the study research team, and read this Participant Information Sheet.
Ph: +61 8 8313 7676
|Chief Investigators||Granting Body||Project Title||Type of Grant||Total Grant Amount||Funding Period|
|Baune BT, Clark SR||Lundbeck||Trajectories of Response to Aripiprazole Maintena Study (TRAMS)||$139,571||Feb 2016 - Feb 2018|
|Stacey D. Clark SR, Baune BT||Royal Adelaide Hospital Research Foundation||Lithium treatment response in bipolar disorder: functional characterisation of a genome-wide association study and a systems biology analysis using next generation RNA sequence data||Clinical Project grant||$48,677||2015|
|Baune BT, Clark SR||SA Health||SA Health Data: Chronic Psychosis: Morbidity, Morality and Service use in South Australia||Linkage grant||$7,200||2014|
International Collaborations include:
- Conligen – The Consortium on Lithium Genetics
- Psychiatric Genetics Consortium (PGC)
|Professor Pat McGorry||Centre for Youth Mental Health||University of Melbourne||Melbourne||Australia|
|Professor Christos Pantellis||Melbourne Neuropsychiatry Centre||University of Melbourne||Melbourne||Australia|
|Assoc. Professor Paul Amminger||Centre for Youth Mental Health||University of Melbourne||Melbourne||Australia|
|Dr Quenten Schwarz||Centre for Cancer Biology||University of South Australia||Melbourne||Australia|